Champions Oncology Inc
NASDAQ:CSBR

Watchlist Manager
Champions Oncology Inc Logo
Champions Oncology Inc
NASDAQ:CSBR
Watchlist
Price: 6.72 USD 6.67% Market Closed
Market Cap: 92.7m USD

Intrinsic Value

The intrinsic value of one CSBR stock under the Base Case scenario is 8.87 USD. Compared to the current market price of 6.72 USD, Champions Oncology Inc is Undervalued by 24%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CSBR Intrinsic Value
8.87 USD
Undervaluation 24%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Champions Oncology Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about CSBR?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is CSBR valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Champions Oncology Inc.

Explain Valuation
Compare CSBR to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about CSBR?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Champions Oncology Inc

Current Assets 21m
Cash & Short-Term Investments 10.3m
Receivables 9.5m
Other Current Assets 1.2m
Non-Current Assets 9.5m
PP&E 9m
Intangibles 335k
Other Non-Current Assets 196k
Current Liabilities 22.7m
Accounts Payable 4.8m
Accrued Liabilities 3.3m
Other Current Liabilities 14.5m
Non-Current Liabilities 4.3m
Long-Term Debt 66k
Other Non-Current Liabilities 4.3m
Efficiency

Free Cash Flow Analysis
Champions Oncology Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Champions Oncology Inc

Revenue
56.9m USD
Cost of Revenue
-29.3m USD
Gross Profit
27.6m USD
Operating Expenses
-24.6m USD
Operating Income
3m USD
Other Expenses
-58k USD
Net Income
3m USD
Fundamental Scores

CSBR Profitability Score
Profitability Due Diligence

Champions Oncology Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.

48/100
Profitability
Score

Champions Oncology Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.

CSBR Solvency Score
Solvency Due Diligence

Champions Oncology Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
53/100
Solvency
Score

Champions Oncology Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CSBR Price Targets Summary
Champions Oncology Inc

Wall Street analysts forecast CSBR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CSBR is 12.24 USD with a low forecast of 12.12 USD and a high forecast of 12.6 USD.

Lowest
Price Target
12.12 USD
80% Upside
Average
Price Target
12.24 USD
82% Upside
Highest
Price Target
12.6 USD
88% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Champions Oncology Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for CSBR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

CSBR Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one CSBR stock?

The intrinsic value of one CSBR stock under the Base Case scenario is 8.87 USD.

Is CSBR stock undervalued or overvalued?

Compared to the current market price of 6.72 USD, Champions Oncology Inc is Undervalued by 24%.

Back to Top